PolTREG S.A.
Piotr Trzonkowski is the CEO of PolTREG S.A. since May 2019 and has held the position of Senior Professor at the Medical University of Gdansk since June 2004. Trzonkowski has an extensive academic background, including roles as an Associate Professor and Research Fellow. Additionally, Trzonkowski served as a Visiting Professor at the University of Chicago and worked as a Postdoctoral Researcher at the Nuffield Department of Surgical Sciences, University of Oxford. The educational foundation is rooted in a degree from Gdański Uniwersytet Medyczny, attained between 1993 and 1999, culminating in the title of lekarz/ profesor doktor habilitowany medycyny, Lekarski.
This person is not in any teams
This person is not in any offices
PolTREG S.A.
PolTREG was established as a spin-off from the Medical University of Gdańsk in order to develop and commercialize patented TREG method. PolTREG is the most advanced company in TREGS cellular therapies worldwide, breakthrough therapies for type 1 diabetes (T1D) and multiple sclerosis (MS). PolTREG has very promising results regarding the safety and efficacy of TREGS therapy (completed phase I/II clinical trials in T1D and phase I in MS), ready for the next phase of trials. The company is after EMA Scientific Advice procedure.